Table 2.
Summary of chemotherapy-based combined cancer treatment
| Combinational type | Agent regimen | Nanoplatform | Cancer type | Ref. | |
|---|---|---|---|---|---|
| In vitro | In vivo | ||||
| Combination with PDT | CPT + PtNP | CPT-TK-HPPH/Pt NP | CT26 | CT26 | 134 |
| Cisplatin + Ce6 | PCT@HCCT | 4T1 | 4T1 | 68 | |
| TPZ + porphyrinic MOFs | TPZ/UCSs | CT26 | CT26 | 135 | |
| CPT + PPa | MPEG-(TK-CPT)-PPa | HCT116 | HCT116 | 136 | |
| DOX + Ps | DOX-loaded; H-LTDC | HCT-116 | HCT-116 | 101 | |
| TPZ + ICG | iNP/IZ | 4T1 | 4T1 | 103 | |
| TPZ +Ce6 | Lip/Ce6/TPZ-PmiRNA | MCF-7 | MCF-7 | 102 | |
| TPZ +Ce6 | TPZ/AI-NVs | HepG2 | HepG2 | 138 | |
| Combination with PTT | SN38-Nif + ZrC NSs | ZrC@prodrug | A549 and SMMC-7721 | SMMC-7721 | 139 |
| DOX + polyaniline | PANI-ES@AOT-V-D | MCF-7 and Hela | MCF-7 | 140 | |
| DXL + AuNPs | Au/Fe3O4/PVA-10%DXL | MCF-7 | MCF-7 | 141 | |
| DOX + PDA | F@PDA-TPP/SS/DOX | B16F10 | B16F10 | 106 | |
| DOX + Bi2Se3 | Bi2Se3/DOX@MPs | H22 | H22 | 142 | |
| DOX + iron oxide nanoparticles | DOX/MNP-PMs | A549 | / | 143 | |
| DOX + MPN | MSN@MPN@DOX | A549 | / | 144 | |
| DOX + B nanosheets | DOX-17AAG@B-PEG-cRGD | MDA-MB-231 | MDA-MB-231 | 145 | |
| DOX + Cu2-xSe | PT-V@TPDOX | MCF-7 and MCF-7/ADR | MCF-7/ADR | 72 | |
| Pt(IV) + IR780 | Pt-I-IR780 NPs | 4T1 | 4T1 | 146 | |
| Tyroservatide + PpIX | PpIX NAs | 4T1, MCF-7, A2780/Taxol and MCF-7/DOX | 4T1 | 147 | |
| DOX/TAX + PpIX | PM-DOX-TAX | MDA-MB-231 | MDA-MB-231 | 105 | |
| DOX + IR820 | LA-IR820/DOX ND | HepG2 | / | 148 | |
| Combination with CDT | TMZ + MnO | iRPPA@TMZ/MnO | C6 | C6 | 149 |
| Cisplatin + Fe(III) | PtH@FeP | 4T1 | 4T1 | 113 | |
| TPZ + Fe(III) | HGTFT | 4T1 | 4T1 | 150 | |
| DOX + Cu (Ⅱ) | DOX@Cu2O-PEG NCs | MCF-7 | MCF-7 | 151 | |
| Cisplatin + EGCG | PTCG NPs |
HepG2 | HepG2 | 112 | |
| DOX + MIL-100 | DMH NPs | MCF-7 | MCF-7 | 108 | |
| Platinum(IV) + MnO2 | UCMnPt | HepG2 | HepG2 | 152 | |
| DOX + MnO2 | AMSNs/DOX | Huh7 | Huh7 | 153 | |
| CPT + MnO2 | MS@MnO2-CPT | U87MG | U87MG | 154 | |
| CPT + Iron oxide NPs | LaCIONPs | A549 | A549 | 155 | |
| platinum(IV) + Fe3+ | Fe-DSCP-PEG-cRGD | C6 | C6 | 156 | |
| DOX + PB | DOX-Au@PB | SMMC-7721 | SMMC-7721 | 157 | |
| DOX + copper/iron(II) | Cu-Fe-MSNs-DOX | Hela | / | 158 | |
| DOX+ MnO2 | MnO2@HMCuS-DOX | MCF-7 | / | 159 | |
| Cisplatin + Fe2/3+ | Pt&Fe3O4@PP | U87 MG | U87 MG | 160 | |
| Vitamin k3 + Cu2+ | Vk3@MOF-199 NPs | 4T1 | 4T1 | 161 | |
| Combination with radiotherapy | DSP + Hf | BM@NCP(DSP)-PEG | 4T1 | 4T1 | 114 |
| Combination with gas therapy | PTX + S-nitrosoalbumin | Ptx@AlbSNO | 4T1 | 4T1 | 115 |
| DOX + NTC | NO-M@DOX | MCF-7/ADR | MCF-7/ADR | 162 | |
| DOX + GSNO | DOX@GSNO-HAPNs | MCF-7 | MCF-7 | 163 | |
| DOX + DEA/NO | DOX@HA-DNB-DEA/NO | SMMC-772 | SMMC-772 | 164 | |
| Combination with immunotherapy | CUR + NLG919 | PEG-CDM-PEI-P(CURDT) | B16F10 | B16F10 | 126 |
| DOX + R837 | PPP-DOX + ACP-R837 | 4T1 | 4T1 | 127 | |
| DTX + GM-CSF | gETL NPs | CT26 | CT26 | 165 | |
| DOX + JQ1 | IRG@JQ1/DOX | 4T1 | 4T1 | 166 | |
| SF + M1-type macrophages | M1/SLNPs | Hepa1-6 | Hepa1-6 | 167 | |
| DOX + siRNA | PEG@D:siRNA | CT26 | CT26 | 124 | |
| DOX + anti-PD-L1 | CM@MON@DOX | 4T1 | 4T1 | 168 | |
| PTX + anti-PD-1 | sAMcP | B16F10 | B16F10 | 125 | |
| Oxaliplatin + ApoA1 mimic peptide | TA-OBL | 4T1 | 4T1 | 169 | |
| DOX +CpG | LMWH/PPD/CpG | B16F10 | B16F10 | 127 | |
| GEM + 1MT | GEM-1MT NPs | B16F10 | B16F10 | 170 | |
| Multiple combination therapy | SN38 + PDA + PZM | FA-PPSM | Eca-109 | Eca-109 | 171 |
| DOX + γ-radiation + Seleninic acid | PSeR/DOX NPs | MDA-MB-231 | MDA-MB-231 | 172 | |
| PTX + IR780 + S-nitrosothiol | HSA-NO | 4T1 | 4T1 | 173 | |
| DOX + Ce6 | PDPC | MCF-7/ADR | MCF-7/ADR | 130 | |
| DOX + BP | BP-DOX | 4T1 | 4T1 | 131 | |
| DOX + BP + aPPL | BP-DcF + aPL | MC-38 | MC-38 | 132 | |
| DTX + PpIX + CpG | FA-CD@PP-CpG | 4T1 | 4T1 | 133 | |
| R837 + IR820 + 1MT | HA/IR820@ZIF-8 + MAN/(R837+1 MT)@ZIF-8 | B16F10 | B16F10 | 174 | |